Non-Invasive Fluid-Based Prostate Cancer Diagnostics
- Technology Application
- Non-invasive test for prostate cancerdiagnosisTherapeutic prognosis assignment based on proteomic analysis
- Detailed Technology Description
- Validated protein markers identified for prostate cancer diagnosisand prognosis in prostate fluid from urine
- *Abstract
-
Few biomarkers for cancers have been identified and finding reliableversions for prostate cancer remain a significant challenge. Currently, no method exists that willdistinguish between organ-confined and extra-prostatic cancers. Here, targeted proteomics and computationalbiology are combined to discover robust proteomic signatures for prostatecancer. Quantitative proteomics conducted in expressed prostatic secretionsfrom men with extraprostatic and organ-confined prostate cancers areidentified. The test is evaluated in patients using targeted proteomics ofexpressed prostatic secretions in urine.Results demonstrate that guided proteomics can discover highly accuratenon-invasive biomarkers. The invention serves to reduce the need for invasivebiopsies that can lead to further complications.
Systematic development of targetedproteomics assays in EPS-urines. (a) Discovery proteomics data from direct-EPSderived from patients with extracapsular (EC) or organ-confined (OC) prostatictumors was used to select putative candidates. Proteotypic peptides from thesecandidates were carefully selected. (b) All peptides that passed the aboveselection criteria were analyzed in clinically stratified EPS-urines (CohortA).
- *Principal Investigator
-
Dr. Thomas Kislinger, Princess Margaret CancerCentre, University Health Network
- *Publications
- Kim Y., et al. Targeted proteomics identifiesliquid-biopsy signatures for extracapsular prostate cancer (2016) Nat Commun Jun 28;7:11906.
- Country/Region
- USA
